Week of June 1, 2026

This week's 13F and real-time position data tracked by BiotechEdge reveals concentrated activity from Perceptive Advisors, one of the sector's most closely watched specialist funds, with a clear rotation toward rare disease and neuroscience-oriented names heading into a catalyst-dense stretch. Perceptive's largest disclosed build centers on Praxis Precision Medicine (PRAX) at an estimated $656.0 million position size, signaling strong conviction in the company's sodium channel franchise ahead of anticipated clinical milestones. The fund also added meaningfully to Ascendis Pharma (ASND) at $350.3 million and Roivant Sciences (ROIV) at $229.5 million, while initiating or expanding a position in Centessa Pharmaceuticals (CNTA) to $208.9 million and Spyre Therapeutics (SYRE) to $190.8 million. On the sell side, Perceptive trimmed Celcuity (CELC) from what remains a sizable $356.9 million stake, and reduced exposure to Nuvalent (NUVL), Edgewise Therapeutics (EWTX), Rhythm Pharmaceuticals (RYTM), and Protagonist Therapeutics (PTGX), suggesting some profit-taking or risk rebalancing across the oncology and metabolic disease verticals.

Convergence signals this week point to several names attracting broad institutional consensus beyond any single fund. Celcuity (CELC) leads the convergence table with eight funds holding a combined $2.4 billion in the stock, a notably high aggregate despite Perceptive's partial trim, suggesting other holders may be absorbing supply. Centessa Pharmaceuticals (CNTA) is held by nine funds totaling $1.2 billion, aligning with Perceptive's incremental buy and reinforcing the view that the company's lixisenatide-adjacent pipeline and SerpinPC program are drawing sustained institutional attention. Xenon Pharmaceuticals (XENE) and Structure Therapeutics (GPCR) each count nine funds among their holders at $891.2 million and $871.4 million respectively, while COMPASS Pathways (CMPS) registers ten-fund ownership at $454.5 million — the highest fund count on the convergence list and a signal worth monitoring given the ongoing regulatory and commercial trajectory for psilocybin-based therapy in treatment-resistant depression.

Binary catalysts this week and next present meaningful event risk across several large-cap and mid-cap names. United Therapeutics (UTHR) has two Phase 2 readouts landing on June